Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 1.00 |
| ▸ | FBP1 | P09467 | 3/20 | 0.81 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | GAK | O14976 | 1/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608178 | 1.00 | EGFR (1.00) | EGFRFBP1ERBB2ABCG2KDM4E | |
| SCHEMBL27906527 | 0.90 | EGFR (0.81) | EGFRFBP1ERBB2ABCG2 | |
| SCHEMBL2974730 | 0.86 | EGFR (1.00) | EGFRFBP1ERBB2ABCG2KDM4E | |
| SCHEMBL2986298 | 0.86 | EGFR (1.00) | EGFRFBP1ERBB2ABCG2EPHB2 | |
| SCHEMBL31060998 | 0.86 | EGFR (1.00) | EGFRFBP1ERBB2ABCG2MAPK1 | |
| SCHEMBL1417740 | 0.86 | EGFR (1.00) | EGFRFBP1ERBB2ABCG2MAPK1 | |
| Hydrochloric Acid SCHEMBL28028745 | 0.85 | EGFR (0.98) | EGFRFBP1ERBB2ABCG2KDM4E | |
| SCHEMBL7222247 | 0.84 | EGFR (1.00) | EGFRFBP1ERBB2 | |
| SCHEMBL2986222 | 0.84 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL2764474 | 0.84 | EGFR (1.00) | EGFRFBP1ERBB2ABCG2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-8778643-B2 | Methods for increasing lipid levels and producing triacylglycerols in algae | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130273620-A1 | METHODS FOR ALTERING LIPIDS IN ALGAE AND YEAST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-17 | — | — | US | disclosed |
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| US-6596726-B1 | Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme | WARNER LAMBERT COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-5679683-A | USEFUL FOR TREATING CANCER, ARTHRITIS, PSORIASIS, VASCULAR RESTENOSIS AND ANGIOGENESIS | WARNER-LAMBERT COMPANY (US) | 1997-10-21 | — | — | US | disclosed |
| EP-0741711-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | ERBB2, EGFR, ERBB4 | EGFR 2/4885FBP1 1231/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.